Advisors Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.95M | Sell |
17,488
-1,518
| -8% | -$225K | 0.04% | 502 |
|
|
2026
Q1 | $2.5M | Sell |
19,006
-4,181
| -18% | -$555K | 0.04% | 532 |
|
|
2025
Q4 | $3.29M | Sell |
23,187
-7,956
| -26% | -$1.15M | 0.06% | 439 |
|
|
2025
Q3 | $4.37M | Sell |
31,143
-546
| -2% | -$74K | 0.07% | 358 |
|
|
2025
Q2 | $3.98M | Sell |
31,689
-5,072
| -14% | -$582K | 0.07% | 373 |
|
|
2025
Q1 | $4.07M | Buy |
36,761
+366
| +1% | +$46.4K | 0.08% | 346 |
|
|
2024
Q4 | $4.97M | Sell |
36,395
-2,181
| -6% | -$270K | 0.09% | 282 |
|
|
2024
Q3 | $4.44M | Buy |
38,576
+4,549
| +13% | +$624K | 0.08% | 315 |
|
|
2024
Q2 | $4.68M | Buy |
34,027
+1,386
| +4% | +$190K | 0.09% | 282 |
|
|
2024
Q1 | $4.5M | Buy |
32,641
+9,708
| +42% | +$1.33M | 0.09% | 292 |
|
|
2023
Q4 | $3.02M | Buy |
22,933
+1,205
| +6% | +$139K | 0.06% | 388 |
|
|
2023
Q3 | $2.44M | Sell |
21,728
-6,148
| -22% | -$647K | 0.05% | 438 |
|
|
2023
Q2 | $2.63M | Sell |
27,876
-12
| -0% | -$1.17K | 0.05% | 429 |
|
|
2023
Q1 | $2.82M | Buy |
27,888
+530
| +2% | +$55.2K | 0.06% | 406 |
|
|
2022
Q4 | $3.27M | Buy |
27,358
+5,790
| +27% | +$678K | 0.07% | 360 |
|
|
2022
Q3 | $2.29M | Buy |
21,568
+1,361
| +7% | +$138K | 0.05% | 462 |
|
|
2022
Q2 | $1.97M | Buy |
20,207
+4,772
| +31% | +$440K | 0.04% | 519 |
|
|
2022
Q1 | $1.45M | Sell |
15,435
-3,413
| -18% | -$289K | 0.02% | 693 |
|
|
2021
Q4 | $1.61M | Sell |
18,848
-1,222
| -6% | -$112K | 0.02% | 682 |
|
|
2021
Q3 | $1.93M | Sell |
20,070
-2,140
| -10% | -$202K | 0.03% | 606 |
|
|
2021
Q2 | $2.16M | Buy |
22,210
+998
| +5% | +$95.7K | 0.03% | 581 |
|
|
2021
Q1 | $2.06M | Buy |
21,212
+668
| +3% | +$70K | 0.03% | 588 |
|
|
2020
Q4 | $1.97M | Buy |
20,544
+2,810
| +16% | +$271K | 0.03% | 560 |
|
|
2020
Q3 | $1.71M | Sell |
17,734
-590
| -3% | -$68.2K | 0.03% | 524 |
|
|
2020
Q2 | $2.24M | Buy |
18,324
+3,351
| +22% | +$370K | 0.04% | 416 |
|
|
2020
Q1 | $1.3M | Buy |
14,973
+2,330
| +18% | +$228K | 0.03% | 551 |
|
|
2019
Q4 | $1.36M | Buy |
12,643
+677
| +6% | +$70.9K | 0.02% | 659 |
|
|
2019
Q3 | $1.08M | Buy |
11,966
+4,636
| +63% | +$433K | 0.02% | 730 |
|
|
2019
Q2 | $619K | Sell |
7,330
-3,170
| -30% | -$260K | 0.01% | 934 |
|
|
2019
Q1 | $925K | Buy |
10,500
+336
| +3% | +$28.1K | 0.02% | 806 |
|
|
2018
Q4 | $726K | Buy |
10,164
+3,134
| +45% | +$300K | 0.01% | 874 |
|
|
2018
Q3 | $864K | Buy |
7,030
+3,628
| +107% | +$412K | 0.01% | 884 |
|
|
2018
Q2 | $334K | Buy |
+3,402
| New | +$305K | 0.01% | 1146 |
|
Other funds holding NBIX
Advisors Asset Management's NBIX Position: Q2 2026 in Review
Advisors Asset Management reduced its Neurocrine Biosciences (NBIX) stake by 8% in Q2 2026, selling an estimated $225K and leaving 17,488 shares worth $2.95M. The position accounts for 0.04% of the portfolio, ranked #502.
Advisors Asset Management first reported a position in NBIX in Q2 2018 and has held it in 33 quarters since. The position peaked at $4.97M in Q4 2024. 775 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Advisors Asset Management held 17,488 shares of Neurocrine Biosciences worth $2.95M as of Q2 2026.
- Advisors Asset Management sold 1,518 Neurocrine Biosciences shares in Q2 2026, an estimated $225K.
- Neurocrine Biosciences made up 0.04% of Advisors Asset Management's portfolio in Q2 2026, its #502 holding.
- Advisors Asset Management first reported a position in Neurocrine Biosciences in Q2 2018 and has held it in 33 quarters since.
- Advisors Asset Management's Neurocrine Biosciences position peaked at $4.97M in Q4 2024.
- 775 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.